Lattice Biologics Ltd
Lattice Biologics Ltd., a biotech company, develops, manufactures, and markets biologics products for use in the field of bone regeneration in dental, spine, and general orthopedic indications worldwide. It develops acellular demineralized bone scaffold, a human cortical bone demineralized that are used in various applications in orthopedic, neurological, trauma, oral/maxillofacial, and reconstru… Read more
Lattice Biologics Ltd (LBLTF) - Total Assets
Latest total assets as of June 2021: $606.43K USD
Based on the latest financial reports, Lattice Biologics Ltd (LBLTF) holds total assets worth $606.43K USD as of June 2021.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Lattice Biologics Ltd - Total Assets Trend (2000–2020)
This chart illustrates how Lattice Biologics Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Lattice Biologics Ltd - Asset Composition Analysis
Current Asset Composition (September 2020)
Lattice Biologics Ltd's total assets of $606.43K consist of 29.9% current assets and 70.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 1.9% |
| Accounts Receivable | $289.58K | 9.6% |
| Inventory | $518.51K | 17.2% |
| Property, Plant & Equipment | $1.51 Million | 50.0% |
| Intangible Assets | $606.43K | 20.1% |
| Goodwill | $606.43K | 20.1% |
Asset Composition Trend (2000–2020)
This chart illustrates how Lattice Biologics Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lattice Biologics Ltd's current assets represent 29.9% of total assets in 2020, an increase from 0.5% in 2000.
- Cash Position: Cash and equivalents constituted 1.9% of total assets in 2020, up from 0.0% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 40.0% of total assets, an increase from 0.0% in 2000.
- Asset Diversification: The largest asset category is property, plant & equipment at 50.0% of total assets.
Lattice Biologics Ltd Competitors by Total Assets
Key competitors of Lattice Biologics Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
Lattice Biologics Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Lattice Biologics Ltd generates 0.82x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Lattice Biologics Ltd is currently not profitable relative to its asset base.
Lattice Biologics Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.02 | 0.11 | 0.43 |
| Quick Ratio | 0.02 | 0.04 | 0.15 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-1.50 Million | $ -7.60 Million | $ -3.89 Million |
Lattice Biologics Ltd - Advanced Valuation Insights
This section examines the relationship between Lattice Biologics Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.13 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 32.7% |
| Total Assets | $3.02 Million |
| Market Capitalization | $10.46K USD |
Valuation Analysis
Below Book Valuation: The market values Lattice Biologics Ltd's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Lattice Biologics Ltd's assets grew by 32.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Lattice Biologics Ltd (2000–2020)
The table below shows the annual total assets of Lattice Biologics Ltd from 2000 to 2020.
| Year | Total Assets | Change |
|---|---|---|
| 2020-09-30 | $3.02 Million | +32.68% |
| 2019-09-30 | $2.27 Million | -25.81% |
| 2018-09-30 | $3.07 Million | -11.04% |
| 2017-09-30 | $3.45 Million | -25.33% |
| 2016-09-30 | $4.62 Million | -23.10% |
| 2015-09-30 | $6.00 Million | +56906.74% |
| 2014-09-30 | $10.53K | -81.32% |
| 2013-09-30 | $56.38K | -69.17% |
| 2012-09-30 | $182.87K | -69.19% |
| 2011-09-30 | $593.49K | -98.19% |
| 2010-09-30 | $32.78 Million | -22.06% |
| 2009-09-30 | $42.06 Million | +15.11% |
| 2008-09-30 | $36.53 Million | -33.00% |
| 2007-09-30 | $54.53 Million | +189.42% |
| 2006-09-30 | $18.84 Million | +124.20% |
| 2005-09-30 | $8.40 Million | +132.85% |
| 2004-09-30 | $3.61 Million | +376.69% |
| 2002-09-30 | $757.09K | -17.37% |
| 2001-09-30 | $916.28K | -7.72% |
| 2000-09-30 | $992.95K | -- |